Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

X4 Pharmaceuticals

Tracked across 1 events · 7 articles · First seen Sep 08, 2026 · Last active Sep 08, 2026

Sentiment
30
Attention
2
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 30
Regulatory
X4 Pharmaceuticals announced a positive outcome from its Type C meeting with the United States — Food and Drug Administration regarding the global 4WARD Phase 3 clinical trial for mavorixafor in chronic neutropenia. The FDA…
Impact: X4 Pharmaceuticals is the sponsor of the 4WARD trial and the developer of mavorixafor. The FDA's agreement to reduce the sample size is a positive regulatory outcome that may reduce trial costs and accelerate development, supporting the company's stock.
Sep 08, 2026 · 7 articles
ERGEN INTELLIGENCE
Track X4 Pharmaceuticals live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.